Medicine and Dentistry
Neoplasm
100%
Pancreas Adenocarcinoma
76%
Hepatocellular Carcinoma
63%
Programmed Death-Ligand 1
56%
Tumor Microenvironment
50%
Nivolumab
47%
CD8 Antigen
47%
T Cell
43%
Metastatic Carcinoma
40%
Colorectal Cancer
35%
Ipilimumab
31%
DNA Mismatch Repair
30%
Immunotherapy
30%
Malignant Neoplasm
28%
Progression Free Survival
28%
Programmed Cell Death
28%
Cabozantinib
26%
Pancreas Cancer
24%
Stroma
23%
Fibrosis
23%
Pancreatic Ductal Adenocarcinoma
23%
Macrophage
22%
Arm
21%
Entinostat
21%
Biliary Atresia
21%
Mucin
21%
Disease
21%
Surgery
20%
Programmed Death 1 Ligand 1
19%
Tumor Infiltrating Lymphocyte
17%
Image Analysis
17%
Cyclophosphamide
16%
Recurrent Disease
16%
Pembrolizumab
15%
Biological Marker
15%
Overall Survival
15%
Neoadjuvant Therapy
15%
Cytoskeleton
14%
Tumor Cell
14%
Monotherapy
14%
Solid Malignant Neoplasm
14%
Protein Expression
14%
Phase II Trials
14%
Cellular Infiltration
13%
Transcriptomics
12%
Cytotoxic T-Cell
12%
Axon Guidance
11%
Cholangiocyte
11%
Clinical Trial
11%
Colon
11%
Keyphrases
Nivolumab
53%
Neoadjuvant
47%
Programmed Death-ligand 1 (PD-L1)
46%
Tumor Microenvironment
44%
Hepatocellular Carcinoma
43%
Pancreatic Ductal Adenocarcinoma
36%
Tumor
30%
Colorectal Cancer
29%
Pancreatic Cancer
25%
CD8+ T Cells
24%
Mismatch Repair
23%
Clinical Trials
23%
Progression-free Survival
21%
Metastatic Pancreatic Ductal Adenocarcinoma
21%
Spatial Landscape
21%
Entinostat
21%
Overall Survival
21%
Ipilimumab
21%
Pancreatic Adenocarcinoma
21%
Multi-omics Analysis
21%
CD-8
20%
Effector T Cells
18%
Neoadjuvant Therapy
16%
Confidence Interval
16%
CD137
15%
Pembrolizumab
15%
Monotherapy
15%
Tumor Cells
15%
Lymphoid Aggregates
15%
Forkhead Box P3 (FOXP3)
14%
Solid Tumors
14%
Pancreatic Duct Cells
14%
Liver
13%
Molecular Interactions
13%
Cabozantinib
13%
Spatial Heterogeneity
13%
Tumor Progression
13%
T Cells
13%
Phase II Study
12%
Vaccine Response
12%
T Cell Infiltration
12%
Locally Advanced
12%
Poor Prognosis
12%
PD-L1 Expression
11%
Human Hepatocellular Carcinoma
11%
Fibrosis
11%
Inflammation
11%
Antitumor Immune Response
11%
Tumor Metastasis
11%
Metastasis
11%
Immunology and Microbiology
CD8
35%
Programmed Death-Ligand 1
31%
Nivolumab
30%
Arm
29%
Vaccine Efficacy
29%
Cytotoxic T-Cell
27%
Overall Survival
27%
Immune Checkpoint Blockade
26%
Programmed Death 1 Ligand 1
25%
T Cell
24%
Immunotherapy
22%
Mismatch Repair
21%
Cabozantinib
21%
Tumor-Infiltrating Lymphocytes
18%
Cyclophosphamide
18%
Macrophage
14%
Cell Infiltration
13%
Stroma
12%
Monospecific Antibody
12%
Gene Expression Profiling
12%
Colon
11%
Colitis
10%
Multi-Omics
10%
Atezolizumab
10%
Pembrolizumab
10%
Heart Transplantation
10%
Ipilimumab
10%
Ulcerative Colitis
10%
Hepatobiliary System
10%
Mucin
10%
Prostate
10%
Cell Death
10%
Cancer Associated Fibroblast
10%
Growth Inhibition
10%
Vaccine Adjuvant
10%
Molecular Interaction
10%
Progression Free Survival
10%
Intravenous Immunoglobulin
10%
Vaccination Policy
10%
Agonist
10%
Methylation
10%
Fibroblast Growth Factor 2
10%
Low Drug Dose
9%
Immunocompetent Cell
8%
Disease Free Survival
8%
Immunity
7%
Transcriptomics
7%
Extracellular Matrix
7%
B Cell
7%
Cell Marker
7%